Why is the FDA cracking down on compounded GLP-1 drugs? What its letters and statements cite
Why is the FDA cracking down on compounded GLP-1 drugs?
FDA’s dated records point to three things: the tirzepatide and semaglutide shortages that allowed wide compounding were declared resolved (December 19, 2024 and February 21, 2025), FDA found telehealth marketing that implied compounded products were the same as FDA-approved drugs (March 3, 2026), and it counted 990 adverse event reports tied to compounded semaglutide as of May 31, 2026. Of the 155 GLP-1 warning letters in this index, 141 cite false or misleading claims or unapproved or misbranded drugs, and 14 cite compounding or manufacturing (CGMP) problems.
The reasons are FDA’s, quoted from its dated statements and letter subject lines. This site does not add its own.
GLP-1 warning letters by year and subject group
| Compounding / adulterated drugs | 0 | 0 | 4 | 4 | 8 |
| False or misleading claims / misbranded | 0 | 0 | 0 | 56 | 56 |
| Manufacturing practice (CGMP) | 0 | 1 | 2 | 3 | 6 |
| Unapproved new drugs / misbranded | 2 | 7 | 2 | 5 | 16 |
| Unapproved or misbranded drugs sold online | 0 | 2 | 60 | 7 | 69 |
Subject groups restate FDA’s subject line on each letter; the exact subject is on the letters page.
FDA’s statements, by date
- Dec 19, 2024: After reevaluating, FDA issued a new decision that the tirzepatide injection shortage is resolved. FDA said it did not intend to take action, for violations that depend on tirzepatide being on the shortage list, against state-licensed pharmacies (section 503A) until February 18, 2025, or outsourcing facilities (section 503B) until March 19, 2025. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Feb 21, 2025: FDA determined that the shortage of semaglutide injection products is resolved. FDA said it did not intend to take action, for violations that depend on semaglutide being on the shortage list, against 503A pharmacies and physicians until April 22, 2025, or 503B outsourcing facilities until May 22, 2025 (or a pending court decision, whichever was later). The same update listed liraglutide injection as in shortage. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Sep 5, 2025: FDA established a “green list” import alert (Import Alert 66-80) for GLP-1 active pharmaceutical ingredients. APIs from facilities on the list may enter; APIs from other sources are subject to detention without physical examination. Source: FDA news release: FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients
- Mar 3, 2026: FDA announced 30 warning letters to telehealth companies for false or misleading claims about compounded GLP-1 products on their websites. FDA said the main violations were claims implying sameness with FDA-approved products, and advertising products branded with the telehealth company’s name without qualification, implying the company is the compounder. FDA called it the second group of letters to telehealth firms since it began acting on misleading direct-to-consumer drug advertising in September 2025. Source: FDA news release: FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s
- Apr 1, 2026: FDA stated that tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list. FDA explained that outsourcing facilities may compound from bulk drug substances only if the substance is on the 503B bulks list or the drug is on the shortage list at the time of compounding, distribution and dispensing. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Apr 1, 2026: FDA restated the section 503A conditions: compounding for an individual patient on a prescription, and not compounding regularly or in inordinate amounts drugs that are essentially copies of a commercially available drug. FDA gave semaglutide combined with vitamin B12 (cyanocobalamin) as an example that may be considered essentially a copy, and said that at this time it does not intend to act against a compounder that fills four or fewer prescriptions of such a product in a calendar month. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Apr 30, 2026: FDA announced a proposal not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list, stating it did not identify a clinical need for outsourcing facilities to compound them from bulk drug substances. FDA said it would consider public comments before a final determination. Source: FDA news release: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
- May 31, 2026: FDA states that as of May 31, 2026 it had received 990 reports of adverse events associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. FDA adds that it is not always possible to determine whether an adverse event directly resulted from the drug, and that federal law does not require state-licensed pharmacies that are not outsourcing facilities to report adverse events to FDA, so it considers events from compounded versions likely underreported. Source: FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- Oct 1, 2026: FDA states it has received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide, where patients measured and self-administered incorrect doses or health care professionals miscalculated doses. Source: FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- Oct 1, 2026: FDA states that salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients than those in the approved drugs, and that it is not aware of any lawful basis for their use in compounding. Source: FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- Oct 1, 2026: FDA states it has warned companies that sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide falsely labeled “for research purposes” or “not for human consumption,” sold directly to consumers with dosing instructions. Source: FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
FDA’s page does not date each paragraph; the date shown is the page’s “content current as of” date.
Common questions
Is the FDA banning compounded semaglutide and tirzepatide?
No FDA statement in this index announces a ban. FDA has set dated conditions: the shortages are resolved, outsourcing facilities may compound from bulk semaglutide or tirzepatide only if it is on the 503B bulks list or the shortage list (neither applied as of April 1, 2026), and on April 30, 2026 FDA proposed not adding them to the bulks list.
When did FDA start sending GLP-1 warning letters to telehealth companies?
The earliest letter labeled “(Telehealth)” in this index is dated Sep 9, 2025. FDA’s March 3, 2026 release called the February 2026 letters the second group since it began acting on misleading drug advertising in September 2025.
Does FDA approve compounded GLP-1 drugs?
No. FDA states that compounded drugs are not FDA-approved, which means it does not review their safety, effectiveness or quality before they are marketed (FDA news release, March 3, 2026).
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- FDA news release: FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients
- FDA news release: FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s
- FDA news release: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
- FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- FDA warning letters (fda.gov full-text search)
Records last pulled Nov 15, 2026. Every entry links to the original public record.